Immunohistochemical analysis of 8 biomarkers on tissue microarray (TMA) of 46 Moroccan invasive breast carcinoma

Mariam Amrani, Habiba Kadiri, Salma Bekarsabein, Lorenzo Memeo, Mohamed Alaoui Belabbas, Mahash Mansukhani

Department of Experimental Oncology, Mediterranean Institute of Oncology, Catania, Italy.
Department of Pathology, Columbia University Medical Center, New York, USA.
Department of Pathology, Institut National d’Oncologie, University Mohamed V Souissi, Rabat, Morocco.

DOI: 10.4236/jbise.2013.610126                

Abstract

Aim of the study: Immunohistochemical evaluation of hormone receptors, Her2/neu, CK5/6, E-cadherin, beta-catenin, p53 and PTEN on Tissue Micro Array (TMA) of 46 Moroccan invasive breast carcinomas. Materials and Methods: The cases comprised 40 invasive ductal carcinomas, 4 invasive lobular carcinomas, 1 mixed carcinoma and 1 invasive colloid carcinoma. TMA paraffin blocs were prepared with the Beecher manual arrayer and immunostaining was performed using standard immunoperoxidase techniques. Results: 58.69% of the cases were ER positive. 43.18% (19/44) were triple negative breast cancers (TNBC) of which 15.78% (3/19) were of the basal phenotype expressing CK5/6. On the other hand, 72.22% (13/18) of the TNBC cases were IDC grade 3. Of the 18 IDC grade 3, 22.22% (4/18) were CK5/6 positive. 41.30% and 10.86% of the cases showed reduced expression of E-cadherin and beta-catenin respectively. Beta-catenin nuclear and cytoplasmic staining was noted in 20% and 97.82% respectively. p53 was overexpressed in 10.86% of the cases whereas PTEN loss or reduced expression was noted in 86.95% of the cases. Conclusion: The aim of our study was to introduce TMA technique in our hospital which is considered a reference institution for cancer in Morocco. Although no statistical study was performed to look for any significance of the results obtained, we found good correlation with some of the data in the literature. To determine the molecular characteristics, if any, of the Moroccan patient, larger multidisciplinary and prospective studies would be interesting in the aim to personalize therapeutic decisions.

Keywords

Invasive Breast Carcinoma; Tissue Micro Array; Hormone Receptors; Her2/Neu; CK5/6; p53; PTEN; Beta-Catenin; E-Cadherin

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	[1] Association Lalla Salma de Lutte Contre le Cancer (2012) Registre des cancers de la région du grand Casablancaannées 2005-2006-2007. http://www.contrelecancer.ma/site_media/uploaded_files/RCRC_-_28_mai_2012.pdf
[2]	Donogan, W.L. (1992) Prognostic factors. Cancer, 70, 1755-1764. http://dx.doi.org/10.1002/1097-0142(19920915)70:4+<1755::AID-CNCR2820701617>3.0.CO;2-G
[3]	Guerbaoui, M. (2000). Le cancer au Maroc. Epidémiologie descriptive. Première Edition, Imprimerie Najah ElJadida.
[4]	Wensheng, L., Santhi, D.K., Sanjay, B., et al. (2006) Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. The Journal of Biological Chemistry, 281, 9837-9840. http://dx.doi.org/10.1074/jbc.C600001200
[5]	Zhang, D., Salto-Tellez, M., Do, E., Choudary Putti, T. and Koay, E.S.C. (2003) Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Human Pathology, 34, 362-368. http://dx.doi.org/10.1053/hupa.2003.60
[6]	O’Malley, F.P., Bilous, M. and Ruschoff, J. (2004) HER2 testing: A global perspective. Pathology International, 54, 17-24.
[7]	Yaziji, H., Goldstein, L.C., Barry, T.S., Werling, R., Hwang, H., Ellis, G.K., et al. (2004) HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 291, 1972-1977. http://dx.doi.org/10.1001/jama.291.16.1972
[8]	Delord, J.P., Vigno, T.S. and Milano, G. (2005) Sensibilité et résistance aux inhibiteurs des récepteurs Erb B. Oncologie, 7, 656-659. http://dx.doi.org/10.1007/s10269-005-0320-z
[9]	Bilous, M., Ades, C., Armes, J., Bishop, J., Brown, R., Cooke, B., et al. (2003) Predicting the HER2 status of breast cancer from basic histopathology data: An analysis of 1500 breast cancers as part of the HER 2000 international study. The Breast, 12, 92-98. http://dx.doi.org/10.1016/S0960-9776(02)00273-4
[10]	Kenneth, C.C., William, F.A., April, F., Lynn, A.G.R. and Otis, W.B. (2001) Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer, 92, 37-45. http://dx.doi.org/10.1002/1097-0142(20010701)92:1<37::AID-CNCR1289>3.0.CO;2-F
[11]	Piekarski, J.H. and Biernat, W. (2006) Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma. Histopathology, 49, 248-255. http://dx.doi.org/10.1111/j.1365-2559.2006.02482.x
[12]	Tiezzi, D.G., Moreira De Andrade, J., Candido Dos Reis, F.J., et al. (2006) Apoptosis induced by neoadjuvant chemotherapy in breast cancer. Pathology, 38, 21-27. http://dx.doi.org/10.1080/00313020500465315
[13]	Chow, L.W.C., Loo, W.T.Y., Wai, C.C.Y., Lui, E.L.H., Zhu, L. and Toi, M. (2005) Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients. Biomedicine & Pharmacotherapy, 59, S298-S301. http://dx.doi.org/10.1016/S0753-3322(05)80050-2
[14]	Banerjee, S., Reis-Filho, J.S., Ashley, S., et al. (2006) Basal-like breast carcinomas: Clinical outcome and response to chemotherapy. Journal of Clinical Pathology, 59, 729-735. http://dx.doi.org/10.1136/jcp.2005.033043
[15]	Ata Türker, A., Binnur, ü.O. and ünsal, H. (2006) Expressions of cyclin D1, p53, bcl-2, and bax in infiltrative ductal carcinoma of the breast: Correlations with clinicopathologic characteristics. The Breast Journal, 12, 391-392. http://dx.doi.org/10.1111/j.1075-122X.2006.00289.x
[16]	Cowin, P., Rowlands, T.M. and Hatsell, S.J. (2005) Cadherins and catenins in breast cancer. Current Opinion in Cell Biology, 17, 499-508. http://dx.doi.org/10.1016/j.ceb.2005.08.014
[17]	Rakha, E.A., Abd El Rehim, D., Pinder, S.E., Lewis, S.A. and Ellis, I.O. (2005) E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology, 46, 685-693. http://dx.doi.org/10.1111/j.1365-2559.2005.02156.x
[18]	Nakopoulou, L., Mylona, E., Papadaki, I., Kavantzas, N., Giannopoulou, I., Markaki, S. and Keramopoulos, A. (2006) Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Modern Pathology, 19, 556-563. http://dx.doi.org/10.1038/modpathol.3800562
[19]	Howe, L.R. and Brown, A.M.C. (2004) Wnt signalling and breast cancer. Cancer Biology and Therapy, 3, 36-41. http://dx.doi.org/10.4161/cbt.3.1.561
[20]	Brown, A.M. (2001) Wnt signaling in breast cancer: Have we come full circle? Breast Cancer Research, 3, 351-355. http://dx.doi.org/10.1186/bcr321
[21]	Tsutsui, S., Inoue, H., Yasuda, K., et al. (2005) Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology, 68, 398-404. http://dx.doi.org/10.1159/000086981
[22]	Bose, S., Crane, A., Hibshoosh, H., Mansukhani, M., Sandweis, L. and Parsons, R. (2002) Reduced expression of PTEN correlates with breast cancer progression. Human Pathology, 33, 405-409. http://dx.doi.org/10.1053/hupa.2002.124721
[23]	Fujita, T., Doihara, H., Kawasaki, K., et al. (2006) PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. British Journal of Cancer, 94, 247-252. http://dx.doi.org/10.1038/sj.bjc.6602926
[24]	Nenutil, R., Smardova, J., Pavlova, S., et al. (2005) Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. The Journal of Pathology, 207, 251-259. http://dx.doi.org/10.1002/path.1838
[25]	Guimaraes Tiezzi, D., Moreira De Andrade, J., Candido Dos Reis, F.J., et al. (2006) Apoptosis induced by neoadjuvant chemotherapy in breast cancer. Pathology, 38, 21-27. http://dx.doi.org/10.1080/00313020500465315
[26]	Pinto, A.E., Andre, S., Laranjeira, C.T. and Soares, J. (2005) Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Patheology, 37, 45-50. http://dx.doi.org/10.1080/00313020400011250
[27]	Ziyaie, D., Hupp, T.R. and Thompson, A.M. (2000) P53 and breast cancer. Breast, 9, 239-246. http://dx.doi.org/10.1054/brst.2000.0199